CoChat

circHIPK3 promotes oxaliplatin-resistance in colorectal cancer through autophagy by sponging miR-637

Open access
Zhang, Yanli, Li, Chen, Liu, Xinfeng, Wang, Yanlei, Zhao, Rui, Yang, Yongmei, Zheng, Xin, Zhang, Yi, Zhang, Xin · 2019 · EBioMedicine
Cited by 131

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Resistance to oxaliplatin-based chemotherapy is a major cause of recurrence in colorectal cancer (CRC) patients. There is increasing evidence indicating that circHIPK3 is involved in the development and progression of tumours. However, little is known about the potential role of circHIPK3 in CRC chemotherapy and its molecular mechanisms in chemoresistance also remain unclear. METHODS: Quantitative real-time PCR was performed to detect circHIPK3 expression in tissues of 2 cohorts of CRC patients who received oxaliplatin-based chemotherapy. The chemoresistant effects of circHIPK3 were assessed by cell viability, apoptosis, and autophagy assays. The relationship between circHIPK3, miR-637, and STAT3 mRNA was confirmed by biotinylated RNA pull-down, luciferase reporter, and western blot assays. FINDINGS: In the pilot study, increased circHIPK3 expression was observed in chemoresistant CRC patients. Functional assays showed that circHIPK3 promoted oxaliplatin resistance, which was dependent on inhibition of autophagy. Mechanistically, circHIPK3 sponged miR-637 to promote STAT3 expression, thereby activating the downstream Bcl-2/beclin1 signalling pathway. A clinical cohort study showed that circHIPK3 was upregulated in tissues from recurrent CRC patients and correlated with tumour size, regional lymph node metastasis, distant metastasis, and survival. INTERPRETATION: circHIPK3 functions as a chemoresistant gene in CRC cells by targeting the miR-637/STAT3/Bcl-2/beclin1 axis and might be a prognostic predictor for CRC patients who receive oxaliplatin-based chemotherapy. FUNDING: National Natural Science Foundation of China (81301506), Shandong Medical and Health Technology Development Project(2018WSB20002), Shandong Key Research and Development Program (2016GSF201122), Natural Science Foundation of Shandong Province (ZR2017MH044), and Jinan Science and Technology Development Plan(201805084, 201805003).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ebiom.2019.09.051

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 49

  1. Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 68, 394
  2. Andre, 2009, Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial, J Clin Oncol, 27, 3109, 10.1200/JCO.2008.20.6771 · DOI · Paper page
  3. Goldberg, 2004, A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer, J Clin Oncol, 22, 23, 10.1200/JCO.2004.09.046 · DOI · Paper page
  4. O'Connell, 2004, Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging, J Natl Cancer Inst, 96, 1420, 10.1093/jnci/djh275 · DOI · Paper page
  5. Mehrpour, 2010, Overview of macroautophagy regulation in mammalian cells, Cell Res, 20, 748, 10.1038/cr.2010.82 · DOI · Paper page
  6. Schaaf, 2016, LC3/GABARAP family proteins: autophagy-(un)related functions, FASEB J, 30, 3961, 10.1096/fj.201600698R · DOI · Paper page
  7. Wu, 2015, Expression and clinical significances of Beclin1, LC3 and mTOR in colorectal cancer, Int J Clin Exp Pathol, 8, 3882
  8. Liu, 2017, The BEACH-containing protein WDR81 coordinates p62 and LC3C to promote aggrephagy, J Cell Biol, 216, 1301, 10.1083/jcb.201608039 · DOI · Paper page
  9. Kim, 2014, Autophagy activity in pulmonary metastatic tumor tissues from colorectal cancer: a pilot study, Yonsei Med J, 55, 1484, 10.3349/ymj.2014.55.6.1484 · DOI
  10. Schmitz, 2016, Prognostic relevance of autophagy-related markers LC3, p62/sequestosome 1, beclin-1 and ULK1 in colorectal cancer patients with respect to KRAS mutational status, World J Surg Oncol, 14, 189, 10.1186/s12957-016-0946-x · DOI · Paper page
  11. Pattingre, 2008, Regulation of macroautophagy by mTOR and Beclin 1 complexes, Biochimie, 90, 313, 10.1016/j.biochi.2007.08.014 · DOI · Paper page
  12. Sahni, 2014, Gene of the month: BECN1, J Clin Pathol, 67, 656, 10.1136/jclinpath-2014-202356 · DOI
  13. Choi, 2014, Absence of autophagy-related proteins expression is associated with poor prognosis in patients with colorectal adenocarcinoma, Gastroenterol Res Pract, 2014, 10.1155/2014/179586 · DOI
  14. O'Donovan, 2015, Lithium modulates autophagy in esophageal and colorectal cancer cells and enhances the efficacy of therapeutic agents in vitro and in vivo, PLoS ONE, 10
  15. Li, 2017, Combination of rapamycin and garlic-derived S-allylmercaptocysteine induces colon cancer cell apoptosis and suppresses tumor growth in xenograft nude mice through autophagy/p62/Nrf2 pathway, Oncol Rep, 38, 1637, 10.3892/or.2017.5849 · DOI
  16. Ren, 2018, MicroRNA-125b reverses oxaliplatin resistance in hepatocellular carcinoma by negatively regulating EVA1A mediated autophagy, Cell Death Dis, 9, 547, 10.1038/s41419-018-0592-z · DOI
  17. Wang, 2017, Overaccumulation of p53-mediated autophagy protects against betulinic acid-induced apoptotic cell death in colorectal cancer cells, Cell Death Dis, 8, e3087, 10.1038/cddis.2017.485 · DOI
  18. Pan, 2019, Knockdown of TRIM65 inhibits autophagy and cisplatin resistance in A549/DDP cells by regulating miR-138-5p/ATG7, Cell Death Dis, 10, 429, 10.1038/s41419-019-1660-8 · DOI
  19. Chen, 2016, Circular RNAs: a new frontier in the study of human diseases, J Med Genet, 53, 359, 10.1136/jmedgenet-2016-103758 · DOI · Paper page
  20. Zheng, 2016, Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs, Nat Commun, 7, 11215, 10.1038/ncomms11215 · DOI · Paper page
  21. Shan, 2017, Circular noncoding RNA HIPK3 mediates retinal vascular dysfunction in diabetes mellitus, Circulation, 136, 1629, 10.1161/CIRCULATIONAHA.117.029004 · DOI · Paper page
  22. Zeng, 2018, CircHIPK3 promotes colorectal cancer growth and metastasis by sponging miR-7, Cell Death Dis, 9, 417, 10.1038/s41419-018-0454-8 · DOI · Paper page
  23. Li, 2017, lncRNA HOTAIR contributes to 5FU resistance through suppressing miR-218 and activating NF-kappaB/TS signaling in colorectal cancer, Mol Ther Nucleic Acids, 8, 356, 10.1016/j.omtn.2017.07.007 · DOI · Paper page
  24. Liu, 2019, Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer, Mol Cancer, 18, 43, 10.1186/s12943-019-0981-7 · DOI · Paper page
  25. Li, 2017, CircHIPK3 sponges miR-558 to suppress heparanase expression in bladder cancer cells, EMBO Rep, 18, 1646, 10.15252/embr.201643581 · DOI · Paper page
  26. Zhou, 2019, circRNA.33186 contributes to the pathogenesis of osteoarthritis by sponging miR-127-5p, Mol Ther, 27, 531, 10.1016/j.ymthe.2019.01.006 · DOI · Paper page
  27. Xiao-Long, 2018, Circular RNA circ_HIPK3 is down-regulated and suppresses cell proliferation, migration and invasion in osteosarcoma, J Cancer, 9, 1856, 10.7150/jca.24619 · DOI
  28. Ke, 2019, CircHIPK3 promotes proliferation and invasion in nasopharyngeal carcinoma by abrogating miR-4288-induced ELF3 inhibition, J Cell Physiol, 234, 1699, 10.1002/jcp.27041 · DOI
  29. Chen, 2018, circHIPK3 regulates cell proliferation and migration by sponging miR-124 and regulating AQP3 expression in hepatocellular carcinoma, Cell Death Dis, 9, 175, 10.1038/s41419-017-0204-3 · DOI · Paper page
  30. Pekarcikova, 2016, c-Myb regulates NOX1/p38 to control survival of colorectal carcinoma cells, Cell Signal, 28, 924, 10.1016/j.cellsig.2016.04.007 · DOI
  31. Del Bufalo, 1996, Effect of cisplatin and c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo, Br J Cancer, 74, 387, 10.1038/bjc.1996.370 · doi:10.1038/bjc.1996.370
  32. Chen, 2019, Circular RNA circHIPK3 modulates autophagy via MIR124-3p-STAT3-PRKAA/AMPKalpha signaling in STK11 mutant lung cancer, Autophagy, 1
  33. Yao, 2019, MiR-382 functions as tumor suppressor and chemosensitizer in colorectal cancer, Biosci Rep, 39, 10.1042/BSR20180441 · DOI
  34. Shiovitz, 2015, Molecular markers predictive of chemotherapy response in colorectal cancer, Curr Gastroenterol Rep, 17, 431, 10.1007/s11894-015-0431-7 · DOI
  35. Alves, 2015, Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy, Oncotarget, 6, 30787, 10.18632/oncotarget.5021 · DOI · Paper page
  36. Goulielmaki, 2016, BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells, Oncotarget, 7, 9188, 10.18632/oncotarget.6942 · DOI · Paper page
  37. Strohecker, 2014, Autophagy promotes BrafV600E-driven lung tumorigenesis by preserving mitochondrial metabolism, Autophagy, 10, 384, 10.4161/auto.27320 · DOI · Paper page
  38. Fulda, 2015, Cell death by autophagy: emerging molecular mechanisms and implications for cancer therapy, Oncogene, 34, 5105, 10.1038/onc.2014.458 · DOI · Paper page
  39. Li, 2018, mir-637 inhibits the proliferation of cholangiocarcinoma cell QBC939 through interfering CTSB expression, Eur Rev Med Pharmacol Sci, 22, 1265
  40. Xu, 2018, Primate-specific miRNA-637 inhibited tumorigenesis in human pancreatic ductal adenocarcinoma cells by suppressing Akt1 expression, Exp Cell Res, 363, 310, 10.1016/j.yexcr.2018.01.026 · DOI
  41. Que, 2015, Decreased miRNA-637 is an unfavorable prognosis marker and promotes glioma cell growth, migration and invasion via direct targeting Akt1, Oncogene, 34, 4952, 10.1038/onc.2014.419 · DOI
  42. Wang, 2019, LncRNA FAL1 promotes carcinogenesis by regulation of miR-637/NUPR1 pathway in colorectal cancer, Int J Biochem Cell Biol, 106, 46, 10.1016/j.biocel.2018.09.015 · DOI
  43. Hu, 2018, Long non-coding RNA KCNQ1OT1 modulates oxaliplatin resistance in hepatocellular carcinoma through miR-7-5p/ ABCC1 axis, Biochem Biophys Res Commun, 503, 2400, 10.1016/j.bbrc.2018.06.168 · DOI
  44. Zhang, 2011, Primate-specific microRNA-637 inhibits tumorigenesis in hepatocellular carcinoma by disrupting signal transducer and activator of transcription 3 signaling, Hepatology, 54, 2137, 10.1002/hep.24595 · DOI
  45. Yu, 2018, Magnolin promotes autophagy and cell cycle arrest via blocking LIF/Stat3/Mcl-1 axis in human colorectal cancers, Cell Death Dis, 9, 702, 10.1038/s41419-018-0660-4 · DOI
  46. Sinha, 2008, The autophagy effector Beclin 1: a novel BH3-only protein, Oncogene, 27, S137, 10.1038/onc.2009.51 · DOI · Paper page
  47. Jin, 2018, CircRNA circHIPK3 serves as a prognostic marker to promote glioma progression by regulating miR-654/IGF2BP3 signaling, Biochem Biophys Res Commun, 503, 1570, 10.1016/j.bbrc.2018.07.081 · DOI · Paper page
  48. Liu, 2018, CircHIPK3 is upregulated and predicts a poor prognosis in epithelial ovarian cancer, Eur Rev Med Pharmacol Sci, 22, 3713
  49. Shibata, 2009, The MAP1-LC3 conjugation system is involved in lipid droplet formation, Biochem Biophys Res Commun, 382, 419, 10.1016/j.bbrc.2009.03.039 · DOI · Paper page

Cited by

Metadata

Authors
Zhang, Y., Li, C., Liu, X., Wang, Y., Zhao, R., Yang, Y., Zheng, X., Zhang, Y., & Zhang, X.
Venue
EBioMedicine
Publisher
Elsevier BV
Published
2019-10
Volume
48
Pages
277-288
ISSN
2352-3964 (ISSN-L)
OpenAlex
W2981221708
Cited by
131
References
10
FWCI
5.23
Type
journal article
Language
en
Open access
gold
Licence
Funders
  • Natural Science Foundation of Shandong Province (ZR2017MH044)
  • Jinan Science and Technology Bureau
  • Key Technology Research and Development Program of Shandong (2016GSF201122)
  • National Natural Science Foundation of China (81301506)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.